Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTekCapital Regulatory News (TEK)

Share Price Information for TekCapital (TEK)

Share Price is delayed by 15 minutes
Get Live Data
5.80    -0.10 (-1.69%)
Bid:
5.70
Ask:
5.90
Spread: 0.20 (3.509%)
Market Cap: £14.92m
TEK Live PriceLast checked at - London Stock Exchange

Intraday TekCapital Share Chart

Guident Update

4 Feb 2022 07:00

RNS Number : 6693A
Tekcapital plc
04 February 2022
 

 

 

 

4th February 2022

Tekcapital Plc

("Tekcapital", the "Company" or the "Group")

Portfolio Company Update: Guident Ltd ("Guident")

 

Tekcapital Plc (AIM: TEK), (OTCQB: TEKCF), the UK intellectual property investment group focused on transforming university technologies into valuable products that can improve people's lives, is pleased to announce that portfolio company Guident has provided an update on some of their recent activities.

 

1. Guident Ltd, the developer of software for improving the safety of autonomous vehicles (AVs) and delivery robots, announced that they have filed their 8th patent application covering improvements to their remote monitoring and control centre for AVs. U.S. patent application #17/579,203 entitled: "Near Real-Time Data and Video Streaming System for a Vehicle, Robot or Drone".

 

"We have achieved what we believe to be one of the lowest glass-to-glass (camera-to-monitor) latencies in the market. This technology is required by teleoperations (which enables a human to remotely monitor and control an autonomous vehicle) as it facilitates rapid image analysis for quick decision making," said Harald Braun, Chairman & CEO of Guident Ltd.

 

2. Guident attended the 2022 Consumer Electronic Show in Las Vegas, and whilst there engaged in meetings with potential customers and partners regarding its teleoperation solution, and was delighted with their feedback and desire to collaborate. Discussions are on-going and the Company will update the market as appropriate.

 

3. Additionally, Guident has announced progress with their regenerative shock absorbers (RSA). They reported that their RSA prototypes have been fabricated and are being evaluated by independent test facilities to confirm their performance and capabilities. Guident is currently in discussions with potential customers and strategic partners to both manufacture and use their RSA's. The picture of the RSA prototype can be found under the following link: https://guident.co/shock-abs.jpg

 

 

The Market

According to Triton Market Research "the last mile AV delivery market autonomous vehicle market is expected to reach $41.7 billion by 2028 with a CAGR of 19%. Contactless or "touch-free" delivery is in high-demand since the COVID 19 pandemic and Guident believes this increased demand will accelerate the roll-out of land-based delivery drones for food and medicines to improve their availability and reduce the costs of these deliveries.

About Guident

Guident commercializes new technology to enhance the safety, efficiency and utility of autonomous vehicles and ground-based drones using its proprietary IP & software apps for remote monitoring and control. To learn more please visit www.guident.co

 

 

 

About Tekcapital plc

Tekcapital creates value from investing in new, university-developed discoveries that can enhance people's lives and provides a range of technology transfer services to help organisations evaluate and commercialise new technologies. Tekcapital is quoted on the AIM market of the London Stock Exchange (AIM: symbol TEK) and is headquartered in the UK. For more information, please visit www.tekcapital.com.

 

LEI: 213800GOJTOV19FIFZ85

 

Tekcapital owns 100% of the share capital of Guident Ltd.

For further information, please contact:

 

Tekcapital Plc 

Via Flagstaff

Clifford M. Gross, Ph.D. 

SP Angel Corporate Finance LLP

(Nominated Adviser and Broker)

+44 (0) 20 3470 0470 

Richard Morrison/Charlie Bouverat (Corporate Finance)

Abigail Wayne / Rob Rees (Corporate Broking)

Flagstaff Strategic and Investor Communications

+44 (0) 20 7129 1474

Tim Thompson/Andrea Seymour/Fergus Mellon

 

Forward Looking Statements

This press release is for informational purposes only. The information herein does not constitute investment advice nor an offer to invest and may contain statements related to our future business and financial performance and future events or developments involving Guident or Tekcapital that may constitute forward-looking statements. These statements may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. We may also make forward-looking statements in other reports, in presentations, in material delivered to customers, stakeholders and in press releases. In addition, our representatives may from time to time make oral forward-looking statements. Such statements may be based on the current expectations and certain assumptions of Guident' and/or Tekcapital's management. Please note that these are subject to a number of risks, uncertainties and factors, including, but not limited to those described in various disclosures. Should one or more of these risks or uncertainties materialise, or should underlying expectations not occur or assumptions prove incorrect, actual results, performance or achievements of Guident or Tekcapital may vary materially from those described explicitly or implicitly in the relevant forward-looking statement. Neither Guident nor Tekcapital intends, nor assumes any obligation, to update or revise these forward-looking statements in light of developments which differ from those anticipated.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCUPUWCPUPPGMW
Date   Source Headline
5th Aug 20211:44 pmRNSNotification of Major Holding
5th Aug 20217:00 amRNSLucyd Appoints Non Executive Director
22nd Jul 20217:00 amRNSLucyd launches Crowdfund
5th Jul 202112:37 pmRNSNotification of Major Holdings
5th Jul 20217:00 amRNSLucyd Signs Canadian Distribution Agreement
1st Jul 20217:00 amRNSNotification of Investor Presentation
15th Jun 20212:05 pmRNSSecond Price Monitoring Extn
15th Jun 20212:00 pmRNSPrice Monitoring Extension
15th Jun 20217:00 amRNSGrant of Share Options
8th Jun 20217:00 amRNSNotice of Investor Presentation 8 June 2021
28th May 202110:40 amRNSResults of Annual General Meeting
28th May 20217:12 amRNSBelluscura First Day of Dealings on AIM
13th May 20217:00 amRNSNotice of AGM
10th May 20217:00 amRNSInvestor Presentation
7th May 20214:41 pmRNSSecond Price Monitoring Extn
7th May 20214:36 pmRNSPrice Monitoring Extension
7th May 20217:15 amRNSBelluscura Intention to Float on AIM
5th May 20217:00 amRNSPortfolio Company Update - Lucyd
4th May 20217:00 amRNSPortfolio Company Update - Guident
30th Apr 20217:00 amRNSFinal Results
1st Apr 20217:00 amRNSPortfolio Company Lucyd Update
31st Mar 20217:00 amRNSTotal Voting Rights
25th Mar 20217:00 amRNSNotification of Major Holdings
22nd Mar 20211:43 pmRNSNotification of Major Holdings
22nd Mar 20217:00 amRNSLucyd Signs Distribution Agreement
19th Mar 20214:21 pmRNSNotification of Major Holdings
19th Mar 202112:36 pmRNSNotification of Major Holdings
18th Mar 20219:05 amRNSSecond Price Monitoring Extn
18th Mar 20219:00 amRNSPrice Monitoring Extension
18th Mar 20217:00 amRNSPlacing to raise £3.8 million
11th Mar 20217:00 amRNSSalarius update
8th Mar 20217:00 amRNSBelluscura FDA Clearance
5th Feb 20217:00 amRNSSalarius Update
4th Feb 20212:05 pmRNSSecond Price Monitoring Extn
4th Feb 20212:00 pmRNSPrice Monitoring Extension
2nd Feb 20212:47 pmRNSNotification of Major Shareholding
1st Feb 202111:05 amRNSSecond Price Monitoring Extn
1st Feb 202111:00 amRNSPrice Monitoring Extension
1st Feb 20219:05 amRNSSecond Price Monitoring Extn
1st Feb 20219:00 amRNSPrice Monitoring Extension
1st Feb 20217:00 amRNSCommencement of Trading OTCQB Venture Mkt in USA
12th Jan 20212:05 pmRNSSecond Price Monitoring Extn
12th Jan 20212:00 pmRNSPrice Monitoring Extension
6th Jan 20217:00 amRNSLucyd -Crowdfunding and launch Lyte E glasses
21st Dec 202012:35 pmRNSHolding(s) in Company
7th Dec 20202:49 pmRNSNotification of Major Holdings
3rd Dec 20203:46 pmRNSNotification of Major Holdings
3rd Dec 20209:05 amRNSSecond Price Monitoring Extn
3rd Dec 20209:00 amRNSPrice Monitoring Extension
3rd Dec 20207:00 amRNSBelluscura Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.